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Abstract 38 
Contemporary medical practice is grounded in rigorous scientific evidence in concert with best 39 
clinical practices and informed shared decision making with patients.  During these times of 40 
uncertainty, disruption, and even anxiety, it becomes especially critical that we engage with our 41 
patients and communities in thoughtful dialogue and realistic expectations regarding 42 
treatments surrounding COVID-19.  The hope for a “miracle” cure and urgency to return back to 43 
normal times can stimulate irrational thought, behavior, and even desperate measures by 44 
individuals or groups.  It becomes especially important that we continue to use reasonable, 45 
informed clinical judgment in discussing the various options with patients. 46 
Commentary 47 
There are real and justifiable concerns about the coronavirus pandemic due to the aggressive 48 
nature of the virus, high transmission rates, and increasing mortalities.  The urgency to develop 49 
mechanisms for widespread antibody testing, therapeutics, and vaccinations for COVID-19 on 50 
the part of governmental agencies, pharmaceutical companies, private industry, and healthcare 51 
institutions is real and time sensitive.  However, if there is one thing we should not forget 52 
during this pandemic, it is that we do not throw out the core foundation of 21st century 53 
medicine, which is grounded in evidence that guides practice recommendations and decisions.  54 
The National Academy of Medicine has advocated for the use of clinical practice guidelines by 55 
clinicians to improve healthcare quality and outcomes based on best practices and patient 56 
preferences that enhance shared decision making.1  The AAO-HNSF has investigated thousands 57 
of dollars, hours of time, and substantial resources developing Clinical Practice Guidelines and 58 
Consensus Statements based on evidence to help guide best practices in otolaryngology 59 
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practice and achieve optimal health outcomes for patients, such as the recently revised 60 
guideline on tonsillectomy.2  I can personally attest to the rigorous process adhered to that 61 
involves extensive searches of databases, analyses of the literature, peer-review, and public 62 
commentary.3  These evidence-based recommendations help provide guidance to millions of 63 
health professionals, institutions, and patients throughout the world.   64 
 65 
With the strong push to bring widespread COVID-19 antibody testing to the market, federal 66 
regulatory oversight has been minimal. Dozens of manufacturers have released antibody tests 67 
for the virus into the marketplace with varied levels of accuracy.4 There is significant concern 68 
regarding high rates of inaccurate results that may provide individuals with incorrect assurances 69 
of immunity to the virus and protection from future infection.  If we base our clinical decisions 70 
on data with questionable accuracy, we run the risk of making recommendations on whom may 71 
return to work, school, or social activites when they are still susceptible to acquiring COVID-19.  72 
These mixed findings regarding sensitivity and specificity of various antibody testing 73 
substantiate the need for clinicians to work closely with patients in providing information and in 74 
helping them to understand and interpret the meaning of any test results.  75 
 76 
On the other hand, we have all attended meetings where a speaker might offer an anecdotal 77 
comment regarding the “off label” use for a medication under certain circumstances.  This 78 
simply means that the FDA approved drug is being used to treat a symptom or condition for 79 
which it was not specifically tested for safety and efficacy.  Under certain circumstances, the 80 
physician is using the medicine in a specific manner within one’s own practice.  This is a very 81 
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different message from the one currently being communicated during the COVID-19 crisis by 82 
governmental and non-healthcare public officials.  One area that has been extremely 83 
controversial and driven by unsubstantiated claims of potential effectiveness is the use of the 84 
antimalaria drug hydroxychloroquine to treat patients hospitalized for coronavirus infection.  85 
Initial enthusiasm for the antimalaria medication came out of anecdotal findings or small non-86 
randomized controlled studies but has gained unprecedented momentum amidst the rush to 87 
find a cure.5 The first tragedy in the U.S. came after an elderly coupled ingested chloroquine 88 
phosphate, a derivative of the antimalaria drug, in an effort to ward off the coronavirus.  The 89 
couple was hospitalized after taking the drug and subsequently the husband died from 90 
respiratory complications.6   Despite unsubstantiated claims that hydroxychloroquine is safe or 91 
effective in treating patients with coronavirus symptoms, state and local governments around 92 
the country have been stockpiling the drug.5  One small retrospective study conducted at a VA 93 
hospital found no evidence that hydroxychloroquine administered either with or without 94 
azithromycin was effective in reducing the need for mechanical ventilation in 368 hospitalized 95 
patients with confirmed COVID-19. However, the researchers did find an increased mortality 96 
rate in those patients who had been treated only with hydroxychloroquine.7   A small clinical 97 
study conducted in France, found no clinical benefits in administering hydroxychloroquine 98 
combined with azithromycin to hospitalized patients with significant comorbidities.8  These 99 
preliminary studies further illustrate the need for scientists and clinicians to rely on well-100 
designed trials to determine medication safety and efficacy before advocating widespread use 101 
in patients.  Although federal agencies have been slow to respond, in late April, the Food and 102 
Drug Administration (FDA) posted a notice on their website warning against the use of 103 
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hydroxychloroquine to treat COVID-19 outside of the hospital setting9 and the CDC reiterated 104 
the FDA’s message that there were no drugs or therapeutics approved at this time for the 105 
prevention or treatment of the virus.10   106 
 107 
We are living and working in unprecedented times where we are faced with many uncertainties 108 
about our health, our families, our economy, and our future.  We are all desperate for answers, 109 
effective treatments, even a cure or perhaps a miracle that will help us return to our normal 110 
lives again or better yet bring us back to that time before the coronavirus even entered our 111 
lives.  But realities tell us that this is not going to occur anytime soon.  That is why it is 112 
particularly important that health professionals remain grounded in evidence and best practices 113 
and maintain open candid dialogue with patients.  The search for a miracle to get us out of this 114 
pandemic can lead to individuals taking drastic measures that are not beneficial and may even 115 
prove to be harmful.  The AAO-HNSF’s hard work in developing evidence-based clinical practice 116 
guidelines for over two decades has been extremely valuable to millions of practicing clinicians 117 
around the globe.  With strong research and expert clinical reasoning, we will overcome COVID-118 
19 like we have done successfully with so many other diseases.   119 
   120 
121 
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